医学
免疫抑制
恶性肿瘤
肺移植
肺癌
移植
肺
器官移植
癌症
肿瘤科
内科学
淋巴增殖性病變
重症监护医学
淋巴瘤
作者
Osnat Shtraichman,Vivek N. Ahya
出处
期刊:Annals of Translational Medicine
[AME Publishing Company]
日期:2020-03-01
卷期号:8 (6): 416-416
被引量:26
标识
DOI:10.21037/atm.2020.02.126
摘要
Lung transplantation is an established therapeutic option for selected patients with advanced lung diseases. As early outcomes after lung transplantation have improved, chronic medical illnesses have emerged as significant obstacles to long-term survival. Among them is post-transplant malignancy, currently representing the 2nd most common cause of death 5-10 years after transplantation. Chronic immunosuppressive therapy and resulting impairment of anti-tumor immune surveillance is thought to have a central role in cancer development after solid organ transplantation (SOT). Lung transplant recipients receive more immunosuppression than other SOT populations, likely contributing to even higher risk of cancer among this group. The most common cancers in lung transplant recipients are non-melanoma skin cancers, followed by lung cancer and post-transplant lymphoproliferative disorder (PTLD). The purpose of this review is to outline the common malignancies following lung transplant, their risk factors, prognosis and current means for both prevention and treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI